Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06718127

Description of the Immune Response to Yellow Fever Vaccination

Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years.

The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Médical de l'Institut Pasteur

Paris, 75015, France

Location status: Recruiting

Location contact

Fabien TAIEB, Dr

CONTACT

[email protected]

1 45 68 80 88 ext. +33

About this study

Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years.

For example, research has shown that the live attenuated BCG vaccine induce non-specific trained immunity, enabling innate immune cells to remember their first encounter and improve their immune status during a second confrontation with similar or different agents.

Other currently available live vaccines, such as BCG , could also "train" innate immune cells.

The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 65
  • Referred for immunisation against yellow fever and typhoid
  • Any person with indication for the following vaccinations :
  • Yellow fever
  • Typhoïd
  • Whose vaccination schedule includes two appointments 7 days apart
  • Whose state of health is compatible with a single 51 ml blood sample collection
  • Have consented to participate in the Ivory2 study
  • Benefiting from a Social Security plan or equivalent

Exclusion criteria

  • Anyone with a contraindication to yellow fever and/or typhoid vaccination.
  • Any person who has been vaccinated against yellow fever and/or typhoid.
  • Anyone who has lived in an endemic area (≥ 1 year) and/or has a history of Typhoid.
  • Anyone who is unable to attend the visit 1-month after the typhoid vaccine injection.
  • Women claiming to be pregnant or breast-feeding
  • Anyone unable to give informed consent for participation

Treatment and study plan

Blood samples collection

Biological

blood samples collected at D0 ,W1, W5, M3 and M6

Primary outcomes

  1. Immunological profile of PBMCs, before and after yellow fever vaccination

    Time frame: 6 months

    Cytokine production assays (e.g. TNFa, IL6, IL1b)

Secondary outcomes

  1. Description of the response to TyphimVi® vaccine

    Time frame: 6 months

    ELISA-based quantification of Anti-Vi antibody level >30 U/mL at week 5, and/or fold increase ≥2 compared with pre-vaccination IgG titer.

Study contacts

Contact information is provided by the study sponsor or research team.

Jessica Quintin, Dr

CONTACT

[email protected]

144389454 ext. +33

Sandrine Fernandes Pellerin

CONTACT

[email protected]

145688179 ext. +33

Sponsors and collaborators

Lead sponsor

Institut Pasteur

Industry

Registry information

Acronym: IVORY2

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Dec 5, 2024
Registry last updated
Jun 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.